Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417

Cullinan Oncology, Inc. a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, announced the completion of its agreement with Taiho Pharmaceutical Co., Ltd. signed in May 2022.
[Cullinan Oncology, Inc.]
Press Release

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News